Search Results for: CRISPR Therapeutics

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

January 14, 2024 / By / 5 Comments
CRISPR Therapeutics

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and …

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

February 1, 2021 / By / 2 Comments
ViaCyte, cell therapy for diabetes

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »

Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics

September 3, 2022 / By / 3 Comments
FDA stem cell policy flow chart.

The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on …

Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC

November 18, 2023 / By / 1 Comment
Sekar Kathiresan, Verve Therapeutics

Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I …

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »

Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns

September 9, 2023 / By / Leave a Comment
CRISPR gene editing

CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to …

Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »

Small positive step for BlueRock Therapeutics Stem Cell Therapy for Parkinson’s

August 28, 2023 / By / 4 Comments
BlueRock Therapeutics, Parkinson's disease, brain imaging

Several groups including Viviane Tabar who is a founding scientist at BlueRock Therapeutics are moving forward on potential cell therapies for Parkinson’s Disease. BlueRock just released some new data that’s worth a look. Check out the new BlueRock poster. In today’s post, I briefly discuss the new data. I also go into the larger context …

Small positive step for BlueRock Therapeutics Stem Cell Therapy for Parkinson’s Read More »

Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL

May 20, 2023 / By / Leave a Comment
Multipotent & totipotent vs pluripotent stem cells, very early human embryos totipotent stem cells

Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might …

Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare

March 4, 2023 / By / Leave a Comment
David Liu, human CRISPR

It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech.  There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads …

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »

Weekly reads: ChatGPT as author, COVID pub concern, CRISPR kit

January 28, 2023 / By / 1 Comment
Sam Altman, OpenAI, Chat GPT

Have you had the chance to play around on ChatGPT, the open AI? It can “talk” to you in text kind of like a person. I have tried it out. It’s quite interesting to type in scientific questions and see what pops out. Often it is high-quality text and solid ideas, but not always. You …

Weekly reads: ChatGPT as author, COVID pub concern, CRISPR kit Read More »

Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis

January 22, 2022 / By / Leave a Comment
CRISPR-Model-Jacob-Corn-e1464305007640

The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I …

Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »